Form 8-K - Current report:
SEC Accession No. 0001193125-25-058306
Filing Date
2025-03-20
Accepted
2025-03-20 07:15:58
Documents
14
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d679677d8k.htm   iXBRL 8-K 24877
2 EX-99.1 d679677dex991.htm EX-99.1 46290
  Complete submission text file 0001193125-25-058306.txt   206799

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sion-20250320.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sion-20250320_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sion-20250320_pre.xml EX-101.PRE 11725
16 EXTRACTED XBRL INSTANCE DOCUMENT d679677d8k_htm.xml XML 3764
Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Filer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42504 | Film No.: 25754485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)